Anaplastic large-cell lymphoma and breast implants: Results from a structured expert consultation process.

Kim, B.; Roth, Carol P.; Young, V. Leroy; Chung, Ki-Wook; Busum, Kristin Van; Schnyer, Christopher; Mattke, Soeren

doi:10.1200/jco.2011.29.15_suppl.e18535

Cited by 24 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast implant-associated ALCL should be classified as its own distinct clinical entity (8,10,19,27,28). It shares features of both systemic and cutaneous ALCL, but does not truly fit into either disease category.…”

Section: Discussionmentioning

confidence: 99%

“…In January 2011, the United States Food and Drug Administration (FDA) published an investigation of ALCL and breast implants, which concluded that there is a possible association between breast implants and ALCL; however, the low incidence of ALCL -0.1 to 0.3 per 100,000 -would make proving causality exceedingly difficult (5,6). A multidisciplinary panel of experts reached a similar conclusion (7,8), suggesting an association without a causal relationship between breast implants and ALCL. Other than asserting that an association between implants and ALCL likely exists, no clear consensus regarding ALCL and breast implants has emerged.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease

Weathers¹,

Wolfswinkel²,

Hatef³

et al. 2013

CAN J PLAST SURG

View full text Add to dashboard Cite

A naplastic large cell lymphoma (ALCL) is the subject of increasing scrutiny among plastic surgeons and the public. Accounting for only 3% of all non-Hodgkin's lymphoma and 0.5% of all breast cancers, ALCL is rare (1-4). Multiple reports have highlighted a possible relationship between ALCL in the breast and breast implants. In January 2011, the United States Food and Drug Administration (FDA) published an investigation of ALCL and breast implants, which concluded that there is a possible association between breast implants and ALCL; however, the low incidence of ALCL -0.1 to 0.3 per 100,000 -would make proving causality exceedingly difficult (5,6). A multidisciplinary panel of experts reached a similar conclusion (7,8), suggesting an association without a causal relationship between breast implants and ALCL. Other than asserting that an association between implants and ALCL likely exists, no clear consensus regarding ALCL and breast implants has emerged.In the literature, contributing factors for implant-associated ALCL have not been established. Of the known cases of ALCL associated with implants, both saline and silicone implants have been documented (5). It has been reported in patients both receiving implants for cosmetic purposes and for reconstruction secondary to cancer (9). Time to presentation after placement of breast implants has ranged from one to 23 years, and patients' age has ranged from 28 to 87 years (6). The most consistent association is that all cases of breast implantassociated ALCL in which cytology is known, demonstrate strong CD30 positivity and are anaplastic lymphoma kinase-1 (ALK-1) negative (5,7,10). Continued vigilance in reporting cases is needed to further elucidate possible contributing factors.The majority of what is known about ALCL is derived from case reports. The data from these reports are somewhat limited in that not all contain complete details. A standard work-up for suspected new cases has been recommended by the FDA to ensure that all pertinent information is obtained from each case in the future (5). This will ensure accurate and complete information, and further the study of ALCL and its relationship with breast implants. Using these new recommendations, we present one case of implant-associated ALCL that presented to our facility. Case presentationA 44-year-old female underwent bilateral subglandular breast augmentation in 2005 in Mexico with 410 mL CUI round-textured silicone implants (Allergan, USA) through an inframammary approach. The patient experienced no immediate postoperative complications and had an uneventful course until her presentation to the Ben Taub General Hospital (Texas, USA) seven years after surgery.In 2012, the patient presented to the Ben Taub General Hospital emergency department complaining of progressive left breast swelling and erythema for three months. The patient denied fever, chills or symptoms of systemic toxicity. The patient had no recent history of trauma or breastfeeding. On presentation, the patient was afebrile and hemodynamical...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease

Weathers¹,

Wolfswinkel²,

Hatef³

et al. 2013

CAN J PLAST SURG

View full text Add to dashboard Cite

show abstract

“…Kim in sod. predlagajo, da se opravi tudi pretočna citometrija (19). Pri pozitivnem izvidu se bolnik napoti na PET-CT ali CT slikanje in/ali biopsijo kostnega mozga, ker služi za ugotavljanje morebitne razširjenosti bolezni (18).…”

Section: Obravnava Bolnicunclassified

“…Pri pozitivnem izvidu se bolnik napoti na PET-CT ali CT slikanje in/ali biopsijo kostnega mozga, ker služi za ugotavljanje morebitne razširjenosti bolezni (18). Ob posvetu z onkologom je potrebno kirurško odstraniti vsadek in popolno odstraniti tkivno ovojnico z izrezom v zdravo ter prepoznati in odstraniti spremenjene bezgavke (19).…”

Section: Obravnava Bolnicunclassified

Anaplastični velikocelični limfom, povezan z vsadki dojk

Bajuk

Ahčan

2017

SlovMedJour

View full text Add to dashboard Cite

IzvlečekPo svetu se vedno več žensk odloča za estetsko korekcijo dojk s silikonskimi vsadki in rekonstrukcijo dojk po zdravljenju karcinoma s tkivnim ekspandrom in silikonskim vsadkom. Ocene pravijo, da ima že več kot 10 milijonov žensk po svetu silikonske vsadke dojk. V literaturi je opisanih približno 200 posameznih primerov bolnic z anaplastičnim velikoceličnim limfomom (angl. anaplastic large cell lymphoma, ALCL), ki se povezuje s silikonskimi vsadki. Gre za redko bolezen, ki se po ocenah pojavlja pri 0,1-0,3/100.000 žensk s silikonskimi vsadki letno. Pri kliničnih znakih je potrebno pomisliti tudi na to, sicer zelo redko obliko ALCL. Bolnice so v povprečju stare 50 let. Pri njih se pozno po operaciji lahko pojavi povečanje dojke, bolečina in asimetrija. Pri diagnosticiranju sta pomembni ultrazvočna in citološka preiskava. Ultrazvočno lahko ugotovimo tekočinsko formacijo (serom) ali solidno tumorsko maso. Zdravljenje je individualno. Zaradi narave tumorja je v večini primerov potrebna odstranitev vsadka in popolna odstranitev tkivne ovojnice, katerima sta redko pridruženi kemo-in radioterapija. Petletno preživetje je odvisno od oblike tumorja in dobro korelira s prisotnostjo seroma ali tumorske mase. Pri seromu, ki je pogostejša oblika, je petletno preživetje 100-odstotno, medtem ko je pri solidni tumorski masi petletno preživetje 75-odstotno. Redkost bolezni predstavlja velik diagnostičen izziv, vendar je zgodnje odkrivanje in zdravljenje ključno za ozdravitev bolnic. AbstractAn increasing number of women worldwide decide for esthetic correction of breasts with silicone implants and post-cancer breast reconstruction with tissue expanders and silicone breast implants. It is estimated that more than 10 million women around the globe have them. There are approximately 200 known cases of patients with anaplastic large cell lymphoma (ALCL) linked with silicone breast implants reported in medical literature. ALCL is a rare disease with an annual incidence of 0.1-0.3/100 000 women with breast silicone implants. In the presence of clinical signs, physician should also consider this rare form of ALCL in differential diagnosis. Patients are on average 50 years old. Long after implantation surgery, the patient may experience breast swelling, pain and/or asymmetry. In diagnostics, ultrasound and cytological examination are required. During ultrasound examination fluid formation (seroma) or solid tumor mass can be detected. Treatment is individualized. Due to tumor nature, implant resection and total capsulectomy are usually indicated; also, chemo-and radiotherapy might rarely be required. Five-year survival rate depends on tumor form and correlates well with clinical findings of seroma or solid mass. In the more frequent form, seroma, five-year survival rate is 100 %, while in the case of solid tumor mass five-year survival rate is 75 %. The rarity of this disease makes it difficult to diagnose, but nevertheless, early detection and treatment are important for better recovery.

show abstract

“…The number of BI-ALCL cases reported in primary augmentation and reconstruction for breast cancer or prophylaxis are nearly equivalent. BI-ALCL most commonly follows an indolent course provided adequate surgical ablation of the implant and surrounding capsule without systemic therapy, but aggressive exceptions, disease progression, and death have been reported (22).…”

Section: Overview Of Bi-alclmentioning

confidence: 99%

Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules

et al. 2017

View full text Add to dashboard Cite

Anaplastic large-cell lymphoma and breast implants: Results from a structured expert consultation process.

Cited by 24 publications

References 0 publications

Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease

Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease

Anaplastični velikocelični limfom, povezan z vsadki dojk

Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules

Contact Info

Product

Resources

About